GUTS Shareholder Alert: October 20, 2026 Lead Plaintiff Deadline in Fractyl Health, Inc. Securities Class Action

Morgan Stanley cut Fractyl Health's (GUTS) price target 75%, to $2.00 from $8.00, and downgraded the stock to Equal-weight. The reassessment follows concerns about an "outlier site" in Revita DMR clinical data, highlighted by Canaccord Genuity, creating a material credibility and valuation overhang for the biotech.